Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirarubicin Prophylaxis for Bladder Recurrence in UTUC
NCT02923557Phase 2Unknown
- Sponsor
- Peking University First Hospital
- Start
- Nov 2016
- Primary completion
- Nov 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirarubicin in bladder cancer (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Intravesical recurrence-free survival at 3 years. Status: unknown.
02
Drugs
pirarubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02923557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923557.